Micellar Nanoparticle (MNP) Technology
The MNP Platform was originally developed by Novavax (Nasdaq listed; NVAX) which successfully developed and launched Estrasorb in the US from this platform. SGN in-licensed all worldwide rights to the MNP Platform from Novavax and Estrasorb marketing rights Ex-North America.
Over the last 6 years we have successfully refined the 1st generation MNP Technology from Novavax to a more stable 2nd generation MNP Technology and have applied it successfully to formulate over 20 compounds. The original Novavax technology had large particle sizes (~500nM) and the emulsions were unstable beyond 6 months. The products had to be shaken to mix and emulsify before use.
The 2nd generation MNP technology developed by SGN leads to finer particle sizes (mean particle diameter ~200nM) and stable nanoemulsions. We have documented stability for over 2 years at room temperature for over 10 compounds and up to 5 years for 2nd generation estrasorb. Further we have successfully scaled up and launched a product in India and have approvals for several more.
With an established nanotechnology platform offering broad applicability, we now will focus on developing NanoCannabinoids immediately upon approval of our DEA application (expected Q2, 2017). Cannabinoids are a group of molecules with exciting medicinal properties but present stability and bioavailability concerns. Their bioavailability is so low, in some cases it is not possible to effectively harness their medicinal properties. We believe the marriage between MNP Technology and Cannabinoids to generate NanoCannabinoids would be a perfect solution and could help successfully overcome the delivery and low bioavailability issues.
We currently have two families of patents pending with the USPTO and anticipate additional filings this year.